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Abstract 
Review on Subcutaneous panniculitis-like T-cell 
lymphoma, with data on clinics and the genes 
possibly involved. 
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Clinics and pathology 
Disease 
Subcutaneous panniculitis-like T-cell lymphoma 
(SPTCL) is a lymphoma derived from cytotoxic α/β 
T cells that preferentially involves subcutaneous 
tissue (Gonzalez, Medeiros et al. 1991; Salhany, 
Macon et al. 1998; Parveen and Thompson 2009). 
The definition of SPTCL was revised in the 2008 
World Health Organization (WHO) classification to 
exclude cases of γ/δ T-cell origin; these latter cases 
are now classified as primary cutaneous T-cell γ/δ 
lymphoma (Harris, Swerdlow et al. 2008). 
Etiology 
No specific etiologic factor has been identified for 
SPTCL. Autoimmune diseases occur in 
approximately 20% of patients and some cases show 
overlapping histologic features with subcutaneous 
lupus (Marzano, Berti et al. 2000). The lesions have 
been associated with rheumatoid arthritis (Levy, 
George et al. 1997), inflammatory bowel disease 
(Hoque, Child et al. 2003), and Sjögren syndrome 
(Yokota, Akiyama et al. 2009) . Lesions occurring 
following transplantation also have been described; 
however, a clear association with Epstein-Barr virus 
or other infectious agents has not been identified 
(Salhany, Macon et al. 1998; Go and Wester 2004; 
Bregman, Yeaney et al. 2005). 
Epidemiology 
SPTCL represents less than 1% of all non-Hodgkin 
lymphomas. It affects both children and adults with 
a median age of onset of 35 years. It is slightly more 
common in women but no racial or ethnic 
predisposition has been reported (Kumar, Krenacs et 
al. 1998; Weenig, Ng et al. 2001; Willemze, Jansen 
et al. 2008). 
Clinics 
Patients with SPTCL typically present with solitary 
or multiple painless subcutaneous nodules or 
plaques. The lesions are most commonly located on 
the lower extremities but the upper extremities and 
trunk may also be involved. The lesions may be 
small or measure several centimeters. The nodules 
may become necrotic but ulceration is rare 
(Willemze, Jansen et al. 2008; Parveen and 
Thompson 2009). Systemic symptoms, including 
fever, fatigue, and weight loss are reported in 
approximately half of cases while hemophagocytic 
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syndrome is seen in 15-20% of cases (Marzano, 
Alessi et al. 1997). 
Pathology 
SPTCL is characterized by a dense subcutaneous 
infiltrate of small to medium-sized lymphoid cells. 
The infiltrate involves the fat lobules, usually with 
relative sparing of septa. Typically, there is minimal 
involvement of the overlying epidermis and dermis. 
The adipocytes characteristically show rimming by 
neoplastic lymphocytes. Macrophages and 
vacuolated histiocytes with associated fat necrosis 
and karyorrhectic debris are commonly present 
(Parveen and Thompson 2009). Erythrophagocytosis 
by histiocytes is occasionally seen (Gonzalez, 
Medeiros et al. 1991; Salhany, Macon et al. 1998; 
Willemze, Jansen et al. 2008). 
By immunohistochemistry, the tumor cells have a 
mature alpha-beta cytotoxic T-cell phenotype and 
are characteristically positive for CD3 and CD8 and 
negative for CD4. The cytotoxic proteins granzyme 
B, TIA-1, and perforin are usually present (Kumar, 
Krenacs et al. 1998). Rarely, there is co-expression 
of CD4 and CD8 while the absence of both CD4 and 
CD8 should prompt consideration of a γ/δ T-cell 
lymphoma (Santucci, Pimpinelli et al. 2003; Kong, 
Dai et al. 2008). 
In situ hybridization for Epstein-Barr virus-encoded 
RNA (EBER) is negative in almost all cases 
(Salhany, Macon et al. 1998). 
Treatment 
Multi-agent chemotherapy has traditionally been 
used for the treatment of SPTCL but more recent 
studies suggest that conservative 
immunosuppressive agents such as cyclosporine, 
steroids or chlorambucil may be as effective and 
should be considered in patients without associated 
hemophagocytic syndrome (Tsukamoto, Katsunobu 
et al. 2006). Local radiation therapy has been used 
effectively in patients presenting with a solitary 
lesion (Willemze, Jansen et al. 2008). For patients 
with more aggressive disease, anthracycline-based 
combination chemotherapeutic regimens with or 
without stem cell transplantation are frequently used 
(Go and Wester 2004). 
Prognosis 
SPTCL generally is a clinically indolent disease with 
a waxing and waning course. The 5-year disease-
specific survival is around 80% (Gonzalez, Medeiros 
et al. 1991; Salhany, Macon et al. 1998). In most 
patients the disease remains confined to the 
subcutaneous tissue, and spread to lymph nodes and 
internal organs is rare. Patients who develop 
hemophagocytic syndrome generally have a poor 
outcome (Aronson, West et al. 1985; Gonzalez, 
Medeiros et al. 1991). Most previous reports of 
SPTCL with a rapidly fatal course in the absence of 
hemophagocytic syndrome are probably attributable 
to inclusion of γ/δ T-cell lymphomas, which have a 
much worse prognosis, in the previous classification 
of SPTCL (Toro, Liewehr et al. 2003). 
Genetics 
Note 
Polymerase chain reaction (PCR) analysis of SPTCL 
has shown clonal rearrangements of the TCR β,  γ, 
and α genes without evidence of clonal 
immunoglobulin gene rearrangements (Ghobrial, 
Weenig et al. 2005; Willemze, Jansen et al. 2008; 
Kong, Dai et al. 2009).  
 
Deletion of NAV3 (neuron navigator 3) gene has 
been identified in approximately 50% of cases by 
fluorescence in situ hybridization (FISH) and loss of 
heterozygosity (LOH) assays (Hahtola, Burghart et 
al. 2008).  
 
Gene expression microarray and quantitative PCR 
analysis have shown upregulated expression of 
indoleamine 2,3-dioxygenase ( IDO1), an 
immunotolerance-inducing gene, along with 
upregulation of Th1 type cytokines, most notably 
IFNG, CXCR3, and CCL5. Over-expression of these 
genes may contribute to the formation of an 
immunosuppressive microenvironment, favorable 
for the neoplastic T-cells  
 
A recent next-generation sequencing study has 
identified recurrent mutations in epigenetic 
modifiers and the PI3K/AKT/mTOR pathway in 
SPTCL, with mutations in ARID1B, SMARCA4, 
CHD4, MTOR, and TSC1 each observed in 3/18 
cases (Li, Lu et al. 2017). 
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Subcutaneous panniculitis-like T-cell lymphoma.  At low power (top), the tumor can be seen infiltrating the fat 




Relatively few cases have been analyzed by 
conventional cytogenetics and no consistent 
abnormalities have been identified. 
Cytogenetics molecular 
Several DNA copy number abnormalities have been 
identified by comparative genomic hybridization 
(CGH), including losses of chromosomes 1p, 2p, 2q, 
5p, 7p, 9q, 10q, 11q, 12q, 16, 17q, 19, 20, and 22, 
and gains of chromosomes 2q, 4q, 5q, 6q, 13q. Some 
of these changes overlapped those seen in other 
cutaneous T-cell lymphomas, whereas alterations of 
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chromosomes 5q and 13q appeared unique to 
SPTCL (Hahtola, Burghart et al. 2008). 
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